ROL

Analyst Note: Rollins, Inc. (ROL)

Date: 2026-06-20 Current Price: $44.96

1. Structural Readiness

• Conservative Entry: — (Pending confirmed breakout above the consolidation ceiling).
• Aggressive/Pre-Breakout Entry: — (Not recommended for conservative sizing; price is currently in the "holding" phase).
• Breakout Level: — (Not yet defined; requires price to close above the upper boundary of the current consolidation range).
• Current Price: $44.96.
• Extension: — (Price is within the consolidation range, not extended above the breakout level).
• ATR Context: Current ATR is 2.8% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 2.8% indicates manageable volatility for a large-cap compounder, well below the "extreme" >8% risk zone).

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Macro Thesis: None. There is no named secular thesis (e.g., "Climate Resilience" or "AI Infrastructure") attached to this name as of 2026-06-20.
• Judgment Basis: Conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals (recurring revenue, M&A execution, margin expansion). Do not invent a macro narrative; judge the name on its operational execution and technical readiness.

3. Business Overview

Rollins, Inc. operates in the Pest and Wildlife Control Services industry, providing essential protection against termites, rodents, and insects to residential and commercial customers.

• Business Model: The company utilizes a hybrid model of Company-owned and franchised locations. As of December 31, 2025, approximately 75% of revenue is recurring services, 10% is ancillary, and 15% is one-time services. This contracted nature provides high visibility into future revenue streams (Evidence E17, E18).
• Growth Drivers:
• Organic Growth: Management expects organic growth of 7% to 8% for 2026, driven by price increases and volume. Price realization is expected to contribute 3% to 4% of growth, outpacing CPI (Evidence E1, E2).
• M&A: The company is executing an aggressive acquisition strategy. As of Dec 31, 2025, they completed 94 acquisitions over three years, including 26 in 2025 alone. In April 2026, they announced the acquisition of Romex Pest Control, a top-40 player (Evidence E6, E20).
• Segment Performance: Q1 2026 showed robust growth across the portfolio: Residential (+9.3%), Commercial (+9.6%), and Termite/Ancillary (+13.5%) (Evidence E4, E12).
• Financial Health:
• Cash Flow: Management anticipates cash flow conversion rates above 100% for 2026 (Evidence E8).
• Cost Structure: Gross margins are seasonally low in Q1 but expected to improve through the peak season (Evidence E3).
• Tax & Interest: Effective tax rate expected under 25%; interest expense projected at $35 million (Evidence E10, E11).
• Scale: The company serves over 2 million customers across 70 countries with 21,946 employees (Evidence E16, E22).

4. Archetype and Conviction

• Archetype: Quality Compounder.
• *Fit:* The company demonstrates the hallmarks of a quality compounder: high recurring revenue (75%), consistent organic growth (98 consecutive quarters of revenue growth per Evidence E15), disciplined capital allocation (M&A), and strong cash conversion.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro tailwind).
• Evidence Quality: High. The evidence base is robust, with multiple primary sources (earnings transcripts, 10-K/10-Q filings) confirming growth, pricing power, and M&A success.
• Structural Quality: Moderate to High. The "forming" coil indicates a healthy consolidation after a strong Q1. The ATR of 2.8% suggests the stock is not overheated or erratic.
• Setup Readiness: Partial. The setup is "forming," meaning the structure is valid, but the breakout trigger has not fired. This is a positive signal but not a confirmed entry.
• Rerating Potential: Dependent on the successful integration of Romex and the realization of the 7-8% organic growth target. The market may re-rate the stock if the "quality compounder" narrative is validated by sustained execution.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners:
• A confirmed breakout above the consolidation ceiling with volume.
• Management raising full-year guidance beyond the current 7-8% organic growth expectation.
• Confirmation that the Romex acquisition accretive to margins in the next quarter.
• Gaps in Evidence:
• Valuation Multiples: No specific P/E or EV/EBITDA multiples are provided in the evidence block for 2026-06-20.
• Breakout Target: No specific price target or extension level is defined for the breakout.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: 98 consecutive quarters of revenue growth; 75% recurring revenue mix; management guidance for 7-8% organic growth and 100%+ cash flow conversion. Key risks: Integration of Romex acquisition; weather impacts on seasonal revenue; failure to sustain price increases if CPI moderates. Sizing hint: Position size should reflect the "forming" status; treat as a partial position awaiting breakout confirmation. Expected path: Price consolidates near current levels while Q2 earnings approach; a breakout occurs if Q2 results confirm the 7-8% growth trajectory and margin expansion. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.